New York-based Innerwell is a ketamine-focused teletherapy provider that offers therapy before, during, and after virtually supervised ketamine doses. The company’s platform also supports peer-to-peer sessions, and guided meditations. It offers training for certified therapists to treat individuals using psychedelics and currently focuses on providing virtual care, with plans to offer in-person treatment later on. The company also plans to incorporate other psychedelics in its treatment, such as MDMA and psilocybin, if they are approved by the FDA.
In June 2022, the company launched from stealth, after raising USD 3 million in a pre-seed funding round led by Greycroft.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.